Compare BBDO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBDO | ILMN |
|---|---|---|
| Founded | 1943 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | BBDO | ILMN |
|---|---|---|
| Price | $2.87 | $129.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 15 |
| Target Price | $2.55 | ★ $117.27 |
| AVG Volume (30 Days) | 58.8K | ★ 1.7M |
| Earning Date | 02-06-2026 | 02-05-2026 |
| Dividend Yield | ★ 5.06% | N/A |
| EPS Growth | ★ 47.11 | N/A |
| EPS | 0.38 | ★ 4.46 |
| Revenue | ★ $16,507,289,161.00 | $4,288,000,000.00 |
| Revenue This Year | $78.26 | N/A |
| Revenue Next Year | $7.53 | $2.08 |
| P/E Ratio | ★ $8.26 | $29.49 |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $1.71 | $68.70 |
| 52 Week High | $3.31 | $153.06 |
| Indicator | BBDO | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 56.87 |
| Support Level | $2.96 | $126.44 |
| Resistance Level | $3.08 | $137.09 |
| Average True Range (ATR) | 0.09 | 3.66 |
| MACD | -0.03 | -0.62 |
| Stochastic Oscillator | 15.00 | 42.96 |
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.